Literature DB >> 27812683

Avoiding Undertreatment of Aggressive Prostate Cancer by Early Use of Chemotherapy.

Evan Y Yu1, Daniel W Lin2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27812683     DOI： 10.1001/jamaoncol.2016.3634

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  3 in total

Review 1.  The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis.

Authors:  Junru Chen; Xingming Zhang; Guangxi Sun; Jinge Zhao; Jiandong Liu; Peng Zhao; Jindong Dai; Pengfei Shen; Hao Zeng
Journal:  Onco Targets Ther       Date:  2018-12-13       Impact factor: 4.147

2.  Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/- Docetaxel.

Authors:  Aurore Carrot; Reza-Thierry Elaidi; Olivier Colomban; Denis Maillet; Michel Tod; Benoit You; Stéphane Oudard
Journal:  Cancers (Basel)       Date:  2022-02-05       Impact factor: 6.639

3.  Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.

Authors:  Stéphane Oudard; Igor Latorzeff; Armelle Caty; Laurent Miglianico; Emmanuel Sevin; Anne Claire Hardy-Bessard; Remy Delva; Frédéric Rolland; Loic Mouret; Franck Priou; Philippe Beuzeboc; Gwenaelle Gravis; Claude Linassier; Philippe Gomez; Eric Voog; Xavier Muracciole; Christine Abraham; Eugeniu Banu; Jean-Marc Ferrero; Alain Ravaud; Ivan Krakowski; Jean-Léon Lagrange; Gaël Deplanque; David Zylberait; Laurence Bozec; Nadine Houede; Stéphane Culine; Reza Elaidi
Journal:  JAMA Oncol       Date:  2019-05-01       Impact factor: 31.777
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.